



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Jürgen Behrens et al.

GAU 1642
Examiner N. Davis

Ser. No. 09/587,574

Filed: June 6, 2000

For CONDUCTINE PROTEIN AND A RELATED AGENT FOR DIAG-
NOSING AND TREATING TUMOR ILLNESSES.

Attorney's Docket 0107-026P

Commissioner of Patents
Washington DC 20231

1642
#9
VC
10-18-01
RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

Sir:

Response to restriction requirement

Please extend the term for response to the outstanding Office letter by 1 month, now to expire on October 27, 2001. Please charge the \$55 small entity time extension fee to deposit account No. 060923.


The examiner's courtesy in reissuing the restriction requirement for the last-filed claims, is appreciated.

Applicant elects the claims of Group III (claims 33-38) for further prosecution. The claims that will not be further under consideration will be deleted after a decision was made as to any possible divisional application.

For examination purposes Sequence ID No. 1 is elected with the understanding that once that sequence is allowable the others in the Group will also be examined.


Respectfully submitted

Goodwin Procter L.L.P.
599 Lexington Avenue, 40th floor
New York 10022
(212)813-8835



Gabriel P. Katona, their attorney

It is hereby certified that this is being mailed, as addressed above, on October 9, 2001.



10/16/2001 YCHADHTC 00000001 060923 09587574
01 FC:215 55.00 CH